Fresenius Medical Care AG reported a 22% decline in first-quarter net profit after booking one-off costs for a significant restructuring of its U.S. clinic network, a move that underscores intensifying financial pressures on health service providers.
The German dialysis specialist said Tuesday its net profit fell to €118 million ($138 million) from €151 million in the same period a year earlier. The company has started to overhaul its U.S. footprint by exiting 64 of up to 100 clinics identified for closure as it seeks to improve efficiency.
The restructuring costs overshadowed a 3% rise in revenue, adjusted for currency effects. The reported net profit, however, came in ahead of consensus analyst forecasts of €109 million, according to data compiled by Vara Research. The company's stock fell 7.25% on the news, signaling investor concern over the near-term costs of the turnaround plan.
The decision to shrink its U.S. network highlights a strategic pivot for Fresenius, the world's largest provider of dialysis products and services. The move aims to boost long-term profitability by shedding underperforming assets. This trend mirrors a broader strain across the U.S. healthcare services sector, where providers are grappling with rising labor expenses, staffing shortages, and government reimbursement rates that often fail to cover the full cost of care, leading to a wave of clinic closures and service reductions by other health systems.
This article is for informational purposes only and does not constitute investment advice.
